Perospirone Free Base | CAS# 150915-41-6 (free base) | atypical antipsychotic

MedKoo Cat#: 414865 | Name: Perospirone Free Base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Perospirone Free Base is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.

Chemical Structure

Perospirone Free Base

CAS#150915-41-6 (free base)

Theoretical Analysis

MedKoo Cat#: 414865

Name: Perospirone Free Base

CAS#: 150915-41-6 (free base)

Chemical Formula: C23H30N4O2S

Exact Mass: 426.2089

Molecular Weight: 426.58

Elemental Analysis: C, 64.76; H, 7.09; N, 13.13; O, 7.50; S, 7.52

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

192052-81-6 (HCl dihydrate) 150915-41-6 (free base) 129273-38-7 (HCl)

Synonym

Perospirone Free Base; Lullan

IUPAC/Chemical Name

1H-Isoindole-1,3(2H)-dione, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-, (3aR,7aS)-rel-

InChi Key

FBVFZWUMDDXLLG-HDICACEKSA-N

InChi Code

InChI=1S/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+

SMILES Code

O=C1N(CCCCN2CCN(C3=NSC4=C3C=CC=C4)CC2)C([C@]5([H])CCCC[C@]15[H])=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 426.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yamaguchi J, Hirayama T, Sadahiro R, Nakahara R, Matsuoka H. Delirium due to Trousseau syndrome treated with memantine and perospirone: A case report. PCN Rep. 2023 Nov 16;2(4):e159. doi: 10.1002/pcn5.159. PMID: 38868734; PMCID: PMC11114402. 2: Kikuchi K, Hasegawa C, Sasaki T, Sato Y, Owada T, Shindo Y, Kawamata Y, Sugawara N, Yasui-Furukori N. Continuous alcohol withdrawal delirium and physical illness-associated delirium in a man brought to the emergency department after a disaster: A case report. Neuropsychopharmacol Rep. 2024 Apr 25. doi: 10.1002/npr2.12446. Epub ahead of print. PMID: 38660963. 3: Watanabe M, Takao C, Maeda C, Nayanar G, Tominaga R, Kimura Y, Tu TTH, Nagamine T, Toyofuku A. The effective perospirone augmentation with clonazepam for treatment-resistant burning mouth syndrome: A case report. Neuropsychopharmacol Rep. 2024 Jun;44(2):464-467. doi: 10.1002/npr2.12425. Epub 2024 Mar 18. PMID: 38500267; PMCID: PMC11144597. 4: Ding J, Yang L, Meng Z, Tian M, Chen Y, Gong Y, Hu J, Wei B, Cui X. Therapeutic drug monitoring of perospirone: The lowest effective plasma concentration in patients with schizophrenia. Asian J Psychiatr. 2023 Dec;90:103832. doi: 10.1016/j.ajp.2023.103832. Epub 2023 Nov 17. PMID: 37980799. 5: Valencia Carlo YE, Saracco-Alvarez RA, Valencia Carlo VA, Vázquez Vega D, Natera Rey G, Escamilla Orozco RI. Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis. Front Psychiatry. 2023 Jun 27;14:1189768. doi: 10.3389/fpsyt.2023.1189768. PMID: 37441144; PMCID: PMC10333591. 6: Hemasree GNS, Satish KS, Rajalekshmi SG, Burri RR, Murthy TPK. Exploration of interaction interface of TRKβ/BDNF through fingerprint analysis to disinter potential agonists. Mol Divers. 2024 Jun;28(3):1531-1549. doi: 10.1007/s11030-023-10673-z. Epub 2023 Jun 30. PMID: 37389778. 7: Duan Y, Qiu F, Zhou J, Liu S, Zhao D, Qiu C. Case report: Progressive skin rash and lymphadenopathy associated with lamotrigine-valproic acid combination in a bipolar adolescent. Front Pharmacol. 2023 Mar 17;14:1106423. doi: 10.3389/fphar.2023.1106423. PMID: 37006998; PMCID: PMC10063788. 8: Odagaki Y, Mikami M, Kinoshita M, Meana JJ, Callado LF, García-Sevilla JA, Borroto-Escuela DO, Fuxe K. Agonistic properties of a series of psychotropic drugs at 5-HT1A receptors in rat and human brain membranes determined by [35S]GTPγS binding assay. Pharmacol Rep. 2023 Apr;75(2):266-275. doi: 10.1007/s43440-023-00448-6. Epub 2023 Jan 13. PMID: 36637685. 9: Miyazaki K. Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient. Neuropsychopharmacol Rep. 2022 Sep;42(3):374-376. doi: 10.1002/npr2.12256. Epub 2022 May 4. PMID: 35508301; PMCID: PMC9515704. 10: Inoue S, Maeda I, Ogawa A, Yoshiuchi K, Terada S, Yamada N. Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. Acta Med Okayama. 2022 Apr;76(2):195-202. doi: 10.18926/AMO/63414. PMID: 35503448. 11: Ding J, Zhang Y, Wan S, Yang L, Cui X, Zhao C, Zhang S, Meng Z. A novel and robust analytical method for the quantification of perospirone in human plasma using an LC-MS/MS system with self-internal standard calibration. Clin Biochem. 2022 Jul-Aug;105-106:49-56. doi: 10.1016/j.clinbiochem.2022.04.006. Epub 2022 Apr 15. PMID: 35436467. 12: Kaur G, Chauhan AS, Prinja S, Teerawattananon Y, Muniyandi M, Rastogi A, Jyani G, Nagarajan K, Lakshmi P, Gupta A, Selvam JM, Bhansali A, Jain S. Cost- effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study. Lancet Public Health. 2022 Jan;7(1):e65-e73. doi: 10.1016/S2468-2667(21)00199-7. Epub 2021 Nov 12. Erratum in: Lancet Public Health. 2022 Jan;7(1):e13. doi: 10.1016/S2468-2667(21)00262-0. PMID: 34774219. 13: Okayasu H, Yasui-Furukori N, Shimoda K. A pregnant woman who experienced auditory hallucinations concurrent with hyperemesis gravidarum: A case report. Neuropsychopharmacol Rep. 2021 Dec;41(4):548-550. doi: 10.1002/npr2.12206. Epub 2021 Sep 2. PMID: 34472727; PMCID: PMC8698677. 14: Obara K, Matsuoka Y, Iwata N, Abe Y, Ikegami Y, Shioda N, Hattori Y, Hamamatsu S, Yoshioka K, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles. Biol Pharm Bull. 2021;44(8):1140-1150. doi: 10.1248/bpb.b21-00363. PMID: 34334499. 15: Kanamori T, Kaneko Y, Yamada K, Suzuki M. Successful Combination Therapy of Trazodone and Fluvoxamine for Pica in Alzheimer's Disease: A Case Report. Front Psychiatry. 2021 Jul 1;12:704847. doi: 10.3389/fpsyt.2021.704847. PMID: 34276453; PMCID: PMC8281115. 16: Kishi T, Ikuta T, Sakuma K, Okuya M, Iwata N. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. J Psychiatr Res. 2021 Jun;138:444-452. doi: 10.1016/j.jpsychires.2021.04.032. Epub 2021 Apr 30. PMID: 33964682. 17: Yu W, Huang J, He S, Zhang L, Shen Y, Li H. Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study. Gen Psychiatr. 2021 Feb 8;34(1):e100289. doi: 10.1136/gpsych-2020-100289. PMID: 33644688; PMCID: PMC7871676. 18: Kurose S, Mimura Y, Uchida H, Takahata K, Kim E, Suzuki T, Mimura M, Takeuchi H. Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. J Clin Psychiatry. 2020 Jul 28;81(5):19r13113. doi: 10.4088/JCP.19r13113. PMID: 32726002. 19: Haranishi Y, Hara K, Terada T. Antihyperalgesic effects of intrathecal perospirone in a rat model of neuropathic pain. Pharmacol Biochem Behav. 2020 Aug;195:172964. doi: 10.1016/j.pbb.2020.172964. Epub 2020 Jun 3. PMID: 32504731. 20: Ishida T, Uchida H, Kaneko S, Sugiyama K, Hamabe Y, Mimura M, Suzuki T. Life-Threatening Serotonin Syndrome Precipitated by Discontinuation of Serotonin-Dopamine Antagonist in the Presence of Serotonergic Agents: A Case Report. Clin Neuropharmacol. 2020 May/Jun;43(3):81-83. doi: 10.1097/WNF.0000000000000385. PMID: 32217863.